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Introduction :
HCY in fec tio n has adve rse e ffec t in all for ms o f rena l replacement modalities 1.4. T he nat ural history o f HCY vira l in fec tio n in d if fe re n t re nal re p lacem e nt mo da lit ies is unpred ictabl e and liver dysfun ction is rapid co mpa red to normal person s 2~.
Materials and Methods:
Retro spective anal ysis of HCY infec ted patients on diffe rent renal replacement therapies ( hoamodialysis (HD), CA PO. kidney transp lantation) was done in a univers ity hospital. Th e pat ients with a minimum follow-up of 6 months after HCY scroccnve rston on eae h modality were taken to study. Patients were subjected to monthly analys is of investigations includi ng liver enzy mes (SGOT, SG PT). HCY was tested by usi ng 3 nl ge neration ELISA and when requi red by HC V RNA by RT PCR. None of the patients in different groups we re treated with interferon the rapy fo r HCY infection because o f the economical co nstra ints and because of chances o f reinfectio n during or after the treatment.
R esults :
In un gro up (23) In CAPO gro up(19 ) age 44±1 2 yrs, sex M : F 15:4, duration of follow-up 28 .3±26,4 months; The liver enzy mes arc abnormal with a mean values of levcis SGOT 34±20 IV/ml, SG PT 30±24 IV/ml. There wa s one ep isode o f fulmi nant hepatitis, w hich led to the mortality. There was no cl inical evidence of cirrhosis of liver during the follow-up pcriod(Tab le -I).
In Renal transplantation gro up (19 ) age 37±1O yrs. Sex M:F 15:4 . durat ion of follow-u p 60±37 mont hs ; Th e liver enzymes are abnorma l with a mean values of levels SGOT 38±1() Hl/ml, SGPT 28± 1O IV/ml, there were 5 episodes of fulminant hepatitis which led to the mort ality. Postmortem reve aled fulmin ant hepat itis in three patie nts (Table -I) . 
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Liver function, wh ich is assessed by the liver enzymes(SGO T and SGPT) arc lowc r in the CA PO group compared to other two groups (Hemod ialysis, Renal Transplant). HCY relatcd fulminant hepat itis was highe r in renal transplant reci pients, which is also reported in previous studies ' .Our study suggest an adva ntage to CAPO as the better mod alit y of ren al replaccment therapy in HCY scroconvcrtcd patient as it offers a lower, sta ble liver enzymes and less episodes fulminant hepat itis. The CA PO is advantageous in way as it prevent the nosocomial spread of He y infection, which was proven in prev ious studies">. In high preva lence centers the treatment for HCY with interferon can he plann ed after patient init iated on CA PO, as there are less chances of re-infection during or after the trcatrnenrv. With these adva ntages CA PO may be cons idered as bette r modality to prevent the spread and also for maintaining the stable liver function in select population with He y infection. The natural survival advantage of the renal transplanta tion as bette r renal replacement therapy need to be weighed agai nst the risk of fulminant hepatitis in the group of He y infected patients.
